ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

CELLCEPT INTRAVENOUS
Organ rejection prophylaxis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

CELLCEPT INTRAVENOUS Rx

Generic Name and Formulations:
Mycophenolate mofetil (as hydrochloride) 500mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free; contains polysorbate 80.

Company:
Genentech, Inc.

Therapeutic Use:

Indications for CELLCEPT INTRAVENOUS:

Organ rejection prophylaxis in allogeneic kidney, heart, or liver transplant patients, in combination with other immunosuppressants.

Adult:

Administer within 24hrs after transplantation. Give by slow IV infusion over ≥2hrs. Kidney or liver: 1g twice daily (2g/day). Heart: 1.5g twice daily (3g/day). May treat up to 14 days. Switch to oral forms when tolerated. Severe renal impairment: see full labeling.

Children:

Not recommended.

Contraindications:

Hypersensitivity to other forms of mycophenolate. IV: polysorbate 80 allergy.

Boxed Warning:

Embryo-fetal toxicity. Malignancies. Serious infections.

Warnings/Precautions:

Embryo-fetal toxicity; rule out pregnancy with serum or urine pregnancy test immediately before starting therapy, then another test 8–10 days later. Repeat pregnancy tests during routine follow-up visits. Increased risk of lymphomas and other malignancies (eg, skin). Avoid sun, UV light. Increased susceptibility to infections (eg, bacterial, fungal, protozoal, new or reactivated viral, opportunistic); monitor and consider reducing immunosuppression if new infections or reactivate viral infections develop. Monitor CBCs weekly for 1 month, twice monthly for next 2 months, then monthly during first year. If ANC <1300/µL, discontinue or reduce dose. Active GI disease or renal impairment (monitor). Hypoxanthine-guanine phosphoribosyl transferase deficiency; avoid. Phenylketonuria (oral susp). Advise patients to avoid blood donation during and for ≥6 weeks after cessation. Elderly. Pregnancy: avoid (esp. 1st trimester). Females of reproductive potential must be counseled on using 2 forms of contraception (or 1 form if using IUDs, tubal sterilization, or if partner has had vasectomy) during therapy, and for 6 weeks after discontinuation unless patient chooses abstinence. Males: use effective contraception and avoid semen donation during and for ≥90 days after discontinuation. Nursing mothers.

See Also:

CELLCEPT CAPSULES

CELLCEPT TABLETS

CELLCEPT ORAL SUSPENSION

Pharmacological Class:

Immunosuppressant.

Interactions:

Avoid concomitant live vaccines. May antagonize oral contraceptives (eg, levonorgestrel); use additional barrier methods. May potentiate acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir; monitor. Antagonized by PPIs, drugs that interfere with enterohepatic recirculation (eg, cholestyramine, rifampin, trimethoprim/sulfamethoxazole, other antibiotics), or drugs that induce glucuronidation (eg, telmisartan); monitor. May be potentiated by drugs that inhibit glucuronidation (eg, isavuconazole). Antagonized by calcium-free phosphate binders (eg, sevelamer), magnesium- or aluminum-containing antacids; may give ≥2hrs after mycophenolate mofetil.

Adverse Reactions:

Diarrhea, leukopenia, anemia, infection, vomiting, nausea, constipation, hypertension, peripheral edema; serious viral infections (eg, polyomavirus-associated nephropathy, progressive multifocal leukoencephalopathy, CMV, HBV, HCV), neutropenia (monitor), pure red cell aplasia (w. concomitant immunosuppressants), malignancies; rare: GI bleeding, ulceration, perforation. IV: phlebitis, thrombosis.

Note:

Encourage pregnant patients to enroll in the Mycophenolate Pregnancy Registry by calling (800) 617-8191.

Metabolism:

Hepatic.

Elimination:

Renal (major), fecal.

REMS:

YES

Generic Availability:

YES

How Supplied:

Caps, Tabs—100, 500; Susp—225mL (w. bottle adapter and 2 oral dispensers); Vials (20mL)—4


Data provided by MPR.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs